Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Status:
Completed
Trial end date:
2010-01-02
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor
cells and slow the growth of CNS tumors.
PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have
recurrent or progressive CNS tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins